Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200092, China
NCT Number: NCT05739487
Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis. Though traditional conservative treatments are widely used, none of them is proved to be effective. A number of meta-analyses and observational studies indicate intravenous thrombolysis to be beneficial in CRAO. Selective intra-arterial thrombolysis (IAT) introducing rt-PA directly into the ophthalmic circulation by super-selective microcatheterization may reduce the complications such as intracranial and systemic hemorrhage. The residual visual field is significant for patients with CRAO who have poor central visual acuity. Thus, it is clinically significant to study the changes in visual fields in eyes with CRAO.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Shanghai, Shanghai Municipality, 200092, China
Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis. Though traditional conservative treatments are widely used, none of them is proved to be effective. The respective responses of brain and retinal tissues to acute ischemia share many features is the rationale for therapeutic thrombolysis in CRAO. Intravenous thrombolysis (IVT) has been a therapeutic choice for CRAO since the 1960s, and in the United States, tPA is currently administered in 5.8% of patients admitted with CRAO. A number of meta-analyses and observational studies indicate intravenous thrombolysis to be beneficial in CRAO. Selective intra-arterial thrombolysis (IAT) introducing rt-PA directly into the ophthalmic circulation by super-selective microcatheterization which has the advantage of reducing the dose of rt-PA reaching the systemic circulation. It is clinically significant to study the changes in visual fields in eyes with CRAO. The short-term temporal changes (≤7-day) of VFDs and the adverse reactions in eyes with CRAO after IAT were investigated to assess the efficacy and safety of the procedure in this retrospective study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
Time frame: 7 days
Change of the visual field index as mean deviation (MD) examed by Humphrey visual field analyzer at 7days
Time frame: 7 days
Change of the visual field index as visual field index (VFI) examed by Humphrey visual field analyzer at 7 days
Time frame: 7 days
best corrected visual acuity of logarithm of the minimum angle of resolution
Time frame: 7 days
Death, symptomatic or asymptomatic intracranial hemorrhage, intraocular hemorrhage
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Other
Changes of Visual Field Defects After Selective Intra-arterial Thrombolysis for Central Retinal Artery Occlusion
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06178055
Arterial Occlusive Diseases, Cardiovascular Diseases
Encino, California, United States
View Trial DetailsNCT04526951
Arterial Occlusive Diseases, Cardiovascular Diseases
Antwerp, Belgium
View Trial DetailsNCT06861985
Arterial Occlusive Diseases, Cardiovascular Diseases
Hsinchu, Taiwan
View Trial DetailsNCT03197194
Arterial Occlusive Diseases, Cardiovascular Diseases
Annecy, France
View Trial Details